Mohammadi, Shooka and Fulop, Tamas and Khalil, Abdelouahed and Ebrahimi, Sara and Hasani, Motahareh and Ziaei, Somayeh and Farsi, Farnaz and Mirtaheri, Elham and Afsharianfar, Mostafa and Heshmati, Javad (2025) Does supplementation with pine bark extract improve cardiometabolic risk factors? A systematic review and meta-analysis. BMC Complementary Medicine and Therapies, 25 (1). p. 71. ISSN 2662-7671, DOI https://doi.org/10.1186/s12906-025-04819-9.
Full text not available from this repository.Abstract
Background Supplementation with pine bark extract (PBE) may improve risk factors associated with cardiometabolic syndrome (CMS). The effects of PBE supplementation on cardiometabolic risk factors were evaluated in this systematic review and meta-analysis of randomized controlled trials (RCTs). Methods A comprehensive search of various databases was performed to identify relevant RCTs published up to September 2024. A random-effects model was employed for the meta-analysis, which included 27 RCTs with 1,685 participants. Results The findings indicated that PBE supplementation significantly reduced systolic blood pressure (SBP) (weighted mean difference (WMD): -2.26 mmHg, 95% confidence interval (CI): -3.73, -0.79; P = 0.003), diastolic blood pressure (DBP) (WMD: -2.62 mmHg, 95% CI: -3.71, -1.53; P < 0.001), fasting blood sugar (FBS) (WMD: -6.25 mg/dL, 95% CI: -9.97, -2.53; P = 0.001), hemoglobin A1c (HbA1c) (WMD: -0.32%, 95% CI: -0.54, -0.11; P = 0.003), body weight (WMD: -1.37 kg, 95% CI: -1.86, -0.88; P < 0.001), and low-density lipoprotein (LDL) cholesterol (WMD: -5.07 mg/dL, 95% CI: -9.21, -0.94; P = 0.016) in the PBE-treated group compared to their untreated counterparts. However, no significant impact of PBE was observed on waist-to-hip ratio (WHR), body mass index (BMI), waist circumference (WC), or serum levels of insulin, high-density lipoprotein (HDL) cholesterol, triglycerides (TG), and total cholesterol (TC). Conclusions Supplementation with PBE may ameliorate specific cardiometabolic risk factors, as indicated by reductions in body weight, DBP, SBP, FBS, LDL, and HbA1c levels. This approach can be regarded as an adjunct therapeutic strategy for CMS management. Further high-quality trials with larger sample sizes and longer durations are required to validate these findings.
| Item Type: | Article |
|---|---|
| Funders: | UNSPECIFIED |
| Uncontrolled Keywords: | Lipid profile; Glycemic parameters; Cardiometabolic syndrome; Oligopin; Pycnogenol; Flavangenol |
| Subjects: | R Medicine > R Medicine (General) |
| Divisions: | Faculty of Medicine > Social & Preventive Medicine |
| Depositing User: | Ms. Juhaida Abd Rahim |
| Date Deposited: | 05 May 2025 07:31 |
| Last Modified: | 05 May 2025 07:31 |
| URI: | http://eprints.um.edu.my/id/eprint/47857 |
Actions (login required)
 |
View Item |
